Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters

被引:123
作者
Almeida, AJ [1 ]
Runge, S [1 ]
Muller, RH [1 ]
机构
[1] FREE UNIV BERLIN,DEPT PHARMACEUT BIOPHARMACEUT & BIOTECHNOL,D-12169 BERLIN,GERMANY
关键词
solid lipid nanoparticles; protein antigens; vaccines; lysozyme;
D O I
10.1016/S0378-5173(97)04885-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Solid lipid nanoparticles (SLN) are an alternative to particulate carriers made of biodegradable polyesters. The SLN have been sought as vehicles for drug molecules, and their production often uses physiological lipids or lipid molecules with an history of safe use in human medicine. However, little has been studied regarding the incorporation of peptides into SLN. This report describes the first studies on the incorporation of lysozyme, as a model peptide, in SLN. Previous to nanoparticles preparation, lysozyme was solubilised, until saturation, into the melted lipid phase. Production was carried out by a cold homogenisation process. The entrapment efficiency was dependent on the initial solubility of the peptide in the lipid phase of the final preparation. The influence of formulation parameters (e.g. type of lipid, time of exposure to different temperatures, pressure and the number of homogenisation cycles) on the integrity and activity of the enzyme, was also assessed. The lysozyme molecule remained intact throughout the process without loosing its activity, as shown by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and the rate of lysis of Micrococcus lysolideikticus, respectively. This study shows that some proteins are able to endure the harsh procedures of formulation by high pressure homogenisation, making possible the use of SLN as antigen carriers for vaccine delivery. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:255 / 265
页数:11
相关论文
共 28 条
  • [1] LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS
    ALLISON, AC
    GREGORIADIS, G
    [J]. NATURE, 1974, 252 (5480) : 252 - 252
  • [2] ALMEIDA AJ, 1993, THESIS U ASTON BIRMI
  • [3] Almeida Antonio J., 1992, Biochemical Society Transactions, V20, p316S
  • [4] BIODEGRADABLE MICROSPHERES AS CONTROLLED-RELEASE TETANUS TOXOID DELIVERY SYSTEMS
    ALONSO, MJ
    GUPTA, RK
    MIN, C
    SIBER, GR
    LANGER, R
    [J]. VACCINE, 1994, 12 (04) : 299 - 306
  • [5] AMSELEM S, 1992, VACCINE RES, V1, P383
  • [6] INCORPORATION OF SOLUBLE-ANTIGENS INTO ISCOMS - HIV GP120 ISCOMS INDUCE VIRUS NEUTRALIZING ANTIBODIES
    BROWNING, M
    REID, G
    OSBORNE, R
    JARRETT, O
    [J]. VACCINE, 1992, 10 (09) : 585 - 590
  • [7] FORMULATION CONCERNS OF PROTEIN DRUGS
    CHEN, T
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1992, 18 (11-12) : 1311 - 1354
  • [8] UNDERSTANDING HOW PROTEINS FOLD - THE LYSOZYME STORY SO FAR
    DOBSON, CM
    EVANS, PA
    RADFORD, SE
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1994, 19 (01) : 31 - 37
  • [9] ACRYLIC MICROSPHERES INVIVO .5. IMMUNOLOGICAL PROPERTIES OF IMMOBILIZED ASPARAGINASE IN MICROPARTICLES
    EDMAN, P
    SJOHOLM, I
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (05) : 576 - 580
  • [10] BIODEGRADABLE AND BIOCOMPATIBLE POLY(DL-LACTIDE-CO-GLYCOLIDE) MICROSPHERES AS AN ADJUVANT FOR STAPHYLOCOCCAL ENTEROTOXIN-B TOXOID WHICH ENHANCES THE LEVEL OF TOXIN-NEUTRALIZING ANTIBODIES
    ELDRIDGE, JH
    STAAS, JK
    MEULBROEK, JA
    TICE, TR
    GILLEY, RM
    [J]. INFECTION AND IMMUNITY, 1991, 59 (09) : 2978 - 2986